Medical Economics December 4, 2024
Key Takeaways
- GLP-1 RA drugs represent a major advancement in obesity treatment, indicating a paradigm shift in managing the condition.
- New pharmacological options for obesity are expected to emerge soon, enhancing treatment possibilities.
- The high cost of GLP-1 RA drugs is a significant barrier, necessitating efforts to reduce prices for broader accessibility.
- Dr. Robert Kushner, an expert in obesity and nutrition, underscores the importance of cost reduction based on his clinical experience.
A physician researcher and author discusses the latest information on...
Today's Sponsors
Today's Sponsor